The Fort Worth Press - VIVOS Therapeutics, Inc. ($VVOS) Signs 12-Part Media Series with New to The Street

USD -
AED 3.672497
AFN 64.499217
ALL 80.84991
AMD 363.721147
ANG 1.790365
AOA 916.999955
ARS 1525.000902
AUD 1.429358
AWG 1.80125
AZN 1.696655
BAM 1.720769
BBD 2.015344
BDT 123.2024
BGN 1.683441
BHD 0.377179
BIF 2998.218331
BMD 1
BND 1.279018
BOB 12.252493
BRL 5.224304
BSD 1.000633
BTN 95.990639
BWP 13.681395
BYN 3.028898
BYR 19600
BZD 2.012441
CAD 1.41831
CDF 2324.999822
CHF 0.832585
CLF 0.024509
CLP 967.749811
CNY 6.71045
CNH 6.707495
COP 3370.42
CRC 454.433476
CUC 1
CUP 24.015028
CVE 97.014302
CZK 21.47195
DJF 178.183674
DKK 6.577404
DOP 59.573457
DZD 133.836454
EGP 52.065199
ERN 15
ETB 163.062433
EUR 0.87995
FJD 2.24175
FKP 0.754339
GBP 0.755095
GEL 2.594988
GGP 0.754339
GHS 11.641892
GIP 0.754339
GMD 74.000115
GNF 8799.890903
GTQ 7.642158
GYD 209.372814
HKD 7.844755
HNL 26.901734
HRK 6.633199
HTG 130.949658
HUF 323.893971
IDR 18020
ILS 3.07101
IMP 0.754339
INR 96.0366
IQD 1310.5
IRR 1374849.999746
ISK 120.57024
JEP 0.754339
JMD 158.398768
JOD 0.709026
JPY 157.291499
KES 129.796993
KGS 87.448495
KHR 4061.324594
KMF 433.00018
KPW 900.000318
KRW 1356.544973
KWD 0.308802
KYD 0.833905
KZT 440.039416
LAK 22451.466454
LBP 89605.352877
LKR 331.202682
LRD 172.102517
LSL 16.443205
LTL 2.95274
LVL 0.60489
LYD 6.400781
MAD 9.635971
MDL 17.690714
MGA 4389.484242
MKD 54.175447
MMK 2099.371601
MNT 3597.221926
MOP 8.085273
MRU 40.085344
MUR 47.609923
MVR 15.460034
MWK 1735.117634
MXN 17.98667
MYR 4.081099
MZN 63.909134
NAD 16.443277
NGN 1321.970098
NIO 36.650012
NOK 9.54732
NPR 153.586197
NZD 1.765495
OMR 0.384498
PAB 1.000629
PEN 3.399978
PGK 4.44425
PHP 62.503986
PKR 277.050204
PLN 3.848375
PYG 5877.280966
QAR 3.645011
RON 4.645502
RSD 103.454032
RUB 84.50042
RWF 1477.356208
SAR 3.755913
SBD 8.026199
SCR 13.896675
SDG 601.502082
SEK 9.97376
SGD 1.278625
SHP 0.754404
SLE 24.60218
SLL 20969.491881
SOS 571.501674
SRD 37.685994
STD 20697.981008
STN 21.7
SVC 8.755174
SYP 13002.000254
SZL 16.43879
THB 33.604995
TJS 9.230681
TMT 3.5
TND 2.963175
TOP 2.40776
TRY 48.999465
TTD 6.791427
TWD 31.842696
TZS 2635.003027
UAH 44.902339
UGX 3916.996969
UYU 40.11121
UZS 11822.496346
VES 856.71525
VND 25967
VUV 118.916544
WST 2.76931
XAF 577.209255
XAG 0.016414
XAU 0.000241289451
XCD 2.70255
XCG 1.803385
XDR 0.707052
XOF 577.209255
XPF 104.924667
YER 236.625039
ZAR 16.42725
ZMK 9001.206495
ZMW 19.48741
ZWL 321.999592
SSP 5712.591905
MXV 2.036498
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

VIVOS Therapeutics, Inc. ($VVOS) Signs 12-Part Media Series with New to The Street
VIVOS Therapeutics, Inc. ($VVOS) Signs 12-Part Media Series with New to The Street

VIVOS Therapeutics, Inc. ($VVOS) Signs 12-Part Media Series with New to The Street

Twelve months of national and global coverage to include long-form interviews, earned media, television commercials, iconic outdoor billboards, and accredited investor events

Text size:

NEW YORK CITY, NEW YORK / ACCESS Newswire / February 5, 2026 / Vivos Therapeutics, Inc. (NASDAQ:VVOS), a medical technology company focused on innovative solutions for breathing and sleep disorders, today announced that it has entered into a 12-part media series agreement with New to The Street, one of the longest-running business television and digital media platforms serving public companies in the U.S. and international markets.

The 12-month series is designed to expand Vivos Therapeutics' visibility among investors, healthcare professionals, and strategic partners through a comprehensive, multi-channel media strategy spanning linear television, digital platforms, social media, outdoor advertising, and live investor engagement.

As part of the agreement, Vivos Therapeutics will receive:

Long-form broadcast interviews distributed nationally and internationally

Earned media coverage supporting corporate milestones and clinical positioning

Television commercials airing as sponsored programming alongside New to The Street broadcasts

Iconic outdoor billboard placements in high-impact financial and metropolitan locations

Accredited investor events, providing direct engagement with screened, invitation-only investor audiences

The series will allow Vivos Therapeutics to consistently communicate its clinical progress, commercial execution, and long-term growth strategy throughout the year.

"Partnering with New to The Street provides a sustained, credible platform to communicate our story to a broad audience of investors and stakeholders," said a spokesperson for Vivos Therapeutics. "This multi-part series supports our commitment to education, transparency, and long-term shareholder engagement."

The first segment in the Vivos Therapeutics series is expected to begin airing in the coming weeks, with coverage continuing throughout the 12-month term.

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. (NASDAQ:VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment solutions for breathing and sleep disorders arising from certain dentofacial abnormalities, including obstructive sleep apnea (OSA) and snoring in adults and children.

Vivos' proprietary technologies have been cleared by the U.S. Food and Drug Administration (FDA) for use in adult patients diagnosed with all severity levels of OSA, as well as moderate-to-severe OSA in pediatric patients ages 6 to 17. The company's groundbreaking Complete Airway Repositioning and Expansion (CARE) devices represent the only FDA 510(k)-cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate-to-severe OSA in children.

OSA affects more than one billion people worldwide, with an estimated 80% or more remaining undiagnosed. Beyond disrupted sleep, OSA is closely linked to numerous serious chronic health conditions. While legacy treatments such as CPAP have addressed symptoms, they are often mechanistic and may not address the underlying anatomical causes of the disorder.

Founded in 2016 and headquartered in Littleton, Colorado, Vivos is working to transform the standard of care for sleep-disordered breathing through innovative technology, education, and strategic collaborations with sleep healthcare providers. The company's comprehensive approach-known as The Vivos Method-offers a proprietary, clinically effective, nonsurgical, noninvasive, and nonpharmaceutical solution, designed to address the root causes of OSA and improve long-term patient outcomes.

For more information, visit www.vivos.com.

About New to The Street

New to The Street is a 17-year-old, nationally and internationally syndicated business television brand that broadcasts weekly on Bloomberg Television as sponsored programming, featuring client interviews and television commercials. The program airs across the United States, MENA (Middle East & North Africa), and Latin America, delivering consistent global exposure.

In addition to its linear television distribution, New to The Street operates one of the largest YouTube subscriber channels in the financial and business media space, with over 4.4 million subscribers on New to The Street TV. The platform combines long-form interviews, earned media, digital amplification, and iconic outdoor advertising to deliver predictable, high-impact visibility for its clients.

https://youtube.com/@newtothestreettv

Media Contact:
Monica Brennan
New to The Street
[email protected]

SOURCE: New to The Street



View the original press release on ACCESS Newswire

G.Dominguez--TFWP